GoAI
Get started
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.15

−$0.02 · -1.71%

Aug 21, 4:00 PM ET

COCP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

28

Weakening

Sentiment

53

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $1.15

52-week range

Current $1.15

Open
$1.185
Previous close
$1.17
Volume
84.97K
Market cap
15.86M USD
50-day average
$1.0048
+14.45% above average
200-day average
$1.0843
+6.06% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.53M USD
P/E (TTM)
-1.49×
P/B (TTM)
15.19×
P/S (TTM)
48.05×
EV / EBITDA
-0.65×
Earnings yield
-79.90%
Free cash flow yield
-74.22%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
205.76%
Operating margin
-3063.64%
Net margin
-3011.52%
Return on equity
-139.49%
Return on assets
-90.93%
Return on invested capital
-115.10%

Financial health

Debt / equity
1.28×
Current ratio
3.68×

Financial statements

Income trends

Operating income

−9.02M USD+49.55%

Net income

−8.83M USD+49.55%
Income trends across reported periods−5.83M USD−17.83M USD−29.84M USD−41.84M USDOperating income, FY2021: −14.22M USDOperating income, FY2022: −38.83M USDOperating income, FY2023: −18.56M USDOperating income, FY2024: −17.88M USDOperating income, FY2025: −9.02M USDNet income, FY2021: −14.19M USDNet income, FY2022: −38.84M USDNet income, FY2023: −17.98M USDNet income, FY2024: −17.5M USDNet income, FY2025: −8.83M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −14.22M USD. Operating income FY2022 −38.83M USD. Operating income FY2023 −18.56M USD. Operating income FY2024 −17.88M USD. Operating income FY2025 −9.02M USD. Net income FY2021 −14.19M USD. Net income FY2022 −38.84M USD. Net income FY2023 −17.98M USD. Net income FY2024 −17.5M USD. Net income FY2025 −8.83M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold5.06M USD12.54M USD15.17M USD12.39M USD8.79M USD
Gross profit−5.06M USD−12.54M USD−15.17M USD−12.39M USD−8.79M USD
Research and development5.06M USD12.54M USD15.17M USD12.39M USD8.79M USD
Selling, general, and administrative3.96M USD5.34M USD5.99M USD5.75M USD5.43M USD
Operating expenses3.96M USD5.34M USD3.39M USD26.44M USD5.43M USD
Interest income134K USD537K USD640K USD2 USD4 USD
Interest expense———2K USD4K USD
Depreciation and amortization376K USD126K USD189K USD185K USD190K USD
Operating income−9.02M USD−17.88M USD−18.56M USD−38.83M USD−14.22M USD
Net income−8.83M USD−17.5M USD−17.98M USD−38.84M USD−14.19M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+14.13%
11 comparable reports
Latest EPS result
-0.23
Estimate -0.17 · Miss by 39.39%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.13-0.28-0.44-0.59Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.32, estimate -0.55, surprise +41.82%, Beat. Q2 2025, reported May 15, 2025: actual -0.23, estimate -0.52, surprise +55.77%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.2, estimate -0.3, surprise +33.33%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.19, estimate -0.22, surprise +13.64%, Beat. Q1 2026, reported Mar 31, 2026: actual -0.17, estimate -0.18, surprise +5.56%, Beat. Q2 2026, reported May 15, 2026: actual -0.17, estimate -0.15, surprise -13.33%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.23, estimate -0.165, surprise -39.39%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.15, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates536K371.5K207K42.5KQ2 '24EstimateQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q2 2024, reported May 13, 2024: actual —, estimate 500K USD, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 100K USD, estimate 225K USD, surprise -55.56%, Miss. Q3 2026, reported Aug 13, 2026: actual 105K USD, estimate 50K USD, surprise +110.00%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate 105K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

Corporate actions

Corporate action history

Stock split

Effective Oct 11, 2022

1:12

Stock split

Effective Jan 24, 2018

1:30

Stock split

Effective Mar 15, 2011

10:1

COCP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding COCP

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
153.56K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
140.19K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research COCP

research.disclaimer